Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravenous L-citrulline to prevent cardiopulmonary bypass-associated acute lung injury complications in children undergoing congenital heart defect repair
MOH_2017-03-22_000269Phase 3Recruiting
- Sponsor
- Asklepion Pharmaceuticals
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute lung injury (ALI) comparing L-citrulline with Placebo (2 arms). Primary endpoints: Need for postoperative mechanical ventilation and Need for postoperative inotropic support. Started Dec 2016; status: recruiting.
02
Drugs
citrulline
03
Conditions
acute lung injury (ALI)
Beyond the preview
Go deeper on MOH_2017-03-22_000269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-22_000269.